Key result
The Gyro Pump C1E3 demonstrated equivalent biocompatibility and hemolysis compared to the BioMedicus pump during cardiopulmonary bypass for CABG, with no thrombus formation or pivot wear observed.
Why the study?
Does the Gyro Pump C1E3 provide equivalent biocompatibility and hemolysis compared to the BioMedicus pump in patients undergoing CABG?
Population
30 consecutive patients undergoing coronary artery bypass grafting under conventional cardiopulmonary bypass
Comparison
Gyro Pump C1E3 for cardiopulmonary bypass vs BioMedicus BP-80 pump for cardiopulmonary bypass
Design
Cohort
Follow-up
up to postoperative day 2
Authors
Loading...
Equivalent biocompatibility in CABG cohort supports further evaluation; does not yet justify practice change without randomized data.
Cohort (n=30)
Does the Gyro Pump C1E3 provide equivalent biocompatibility and hemolysis compared to the BioMedicus pump in patients undergoing CABG?
The Gyro Pump C1E3 demonstrates equivalent biocompatibility and hemolysis to the standard BioMedicus pump during cardiopulmonary bypass for CABG.
Orime et al. (2000) conducted a cohort in Coronary artery bypass grafting (CABG) (n=30). Gyro Pump C1E3 vs. BioMedicus BP-80 pump was evaluated on Biocompatibility and hemolysis (plasma free hemoglobin, beta-TG, PF-4, complement activation, coagulation parameters, and endothelial markers). The Gyro Pump C1E3 demonstrated equivalent biocompatibility and hemolysis compared to the BioMedicus pump during cardiopulmonary bypass for CABG, with no thrombus formation or pivot wear observed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: